GSK has opened its newest global vaccines R&D center -- the drugmaker's first fully dedicated vaccines R&D center located in the US. -- in Rockville, Maryland.
The new facility will create up to 200 new jobs, with GSK investing over $50 million in the next two years to continue to develop the site with latest state-of-the-art scientific research technology and equipment.
The facility will house a total of 12 critical vaccine development programs, including projects supporting GSK's candidate shingles vaccine, which was filed for approval with the US FDA in October 2016. Additionally, R&D programs for respiratory syncytial virus (RSV), a major cause of respiratory infections in young children and the elderly, Group B Streptococcus (GBS), a bacterial infection affecting newborns, and dengue fever will be based at the site.
Read the GSK press release